Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.

International journal of cancer - 15 Jun 2014

Kohonen-Corish Maija R J, Tseung Jason, Chan Charles, Currey Nicola, Dent Owen F, Clarke Stephen, Bokey Les, Chapuis Pierre H

Abstract excerpt

Colonic and rectal cancers differ in their clinicopathologic features and treatment strategies. Molecular markers such as gene methylation, microsatellite instability and KRAS mutations, are becoming increasingly important in guiding treatment decisions in colorectal cancer. However, their association with clinicopathologic variables and utility in the management of rectal cancer is still poorly understood. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Methylation

Share to DNA, Neoplasm

Share to Mutation

Share to Promoter Regions, Genetic

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 24259266
DOI: 10.1002/ijc.28619

Genes

KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.PMID 24259266Read ↗

Actionable Molecular Pathways in Colorectal CancerSemantic proximity Read ↗

Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas.Semantic proximity Read ↗

Redefining Therapeutic Approaches in Colorectal Cancer: Targeting Molecular Pathways and Overcoming Resistance.Semantic proximity Read ↗

Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkersSemantic proximity Read ↗

Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer.Semantic proximity Read ↗

DNA methylation predicts recurrence from resected stage III proximal colon cancer.Semantic proximity Read ↗

DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies.Semantic proximity Read ↗

Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics.Semantic proximity Read ↗

CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer.Semantic proximity Read ↗

CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon CancerSemantic proximity Read ↗

Meta-analysis of the prognostic value of CpG island methylator phenotype in rectal cancer.Semantic proximity Read ↗

Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.